U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07330778) titled 'A Study of CDX-622 in Participants With Mild to Moderate Asthma' on Sept. 26, 2025.
Brief Summary: This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Mild to Moderate Asthma
Intervention:
DRUG: CDX-622
Administered Intravenously
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Celldex Therapeutics
Published by HT Digital Content Services with permission from Health Daily Digest....